Korean drugmakers urged to develop biosimilars

Published: 2009-02-04 07:00:00

Updated: 2009-02-04 07:00:00

Domestic pharmaceutical firms will need to focus on development of promising biosimilars or similar biologics, considering the lack of money and resources to develop new drugs, according to market experts.

Unlike the more common "small-molecule" drugs, biologics generally exhibit high molecula...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK